MX9603889A - Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional. - Google Patents
Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.Info
- Publication number
- MX9603889A MX9603889A MX9603889A MX9603889A MX9603889A MX 9603889 A MX9603889 A MX 9603889A MX 9603889 A MX9603889 A MX 9603889A MX 9603889 A MX9603889 A MX 9603889A MX 9603889 A MX9603889 A MX 9603889A
- Authority
- MX
- Mexico
- Prior art keywords
- uterine bleeding
- dysfunctional uterine
- progesterone antagonists
- antagonists useful
- preparing medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los antagonistas competitivos de la progesterona (antigestágenos) son apropiados para la produccion de agentes farmacéuticos para el tratamiento de formas de sangrado uterino disfuncional (metrorragias, menorragias e hipermenorrea).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1995/000394 WO1996023503A1 (de) | 1995-02-02 | 1995-02-02 | Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9603889A true MX9603889A (es) | 1997-04-30 |
Family
ID=8165951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9603889A MX9603889A (es) | 1995-02-02 | 1995-02-02 | Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional. |
Country Status (20)
Country | Link |
---|---|
US (1) | US6451780B1 (es) |
EP (1) | EP0806952B1 (es) |
JP (1) | JPH10512889A (es) |
KR (1) | KR100370908B1 (es) |
AT (1) | ATE235907T1 (es) |
AU (1) | AU714959B2 (es) |
CA (1) | CA2186953C (es) |
DE (1) | DE59510626D1 (es) |
DK (1) | DK0806952T3 (es) |
ES (1) | ES2196063T3 (es) |
FI (1) | FI117850B (es) |
HU (1) | HU226276B1 (es) |
MX (1) | MX9603889A (es) |
NO (1) | NO964155D0 (es) |
NZ (1) | NZ287024A (es) |
PL (1) | PL316533A1 (es) |
PT (1) | PT806952E (es) |
SK (1) | SK282570B6 (es) |
UA (1) | UA37259C2 (es) |
WO (1) | WO1996023503A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2295050T3 (es) | 1999-08-31 | 2008-04-16 | Bayer Schering Pharma Aktiengesellschaft | Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas. |
US8193252B1 (en) * | 1999-08-31 | 2012-06-05 | Bayer Pharma AG | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
US6685626B2 (en) | 2001-02-02 | 2004-02-03 | Regeneration Technologies, Inc. | Compositions, devices, methods, and kits for induction of adhesions |
US20020176893A1 (en) * | 2001-02-02 | 2002-11-28 | Wironen John F. | Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue |
US20080182841A1 (en) * | 2001-10-29 | 2008-07-31 | Levine Howard L | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US7556150B2 (en) * | 2004-06-07 | 2009-07-07 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of DUB |
US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
PL2148681T3 (pl) * | 2007-04-20 | 2016-09-30 | Selektywny modulator progesteronu w leczeniu krwawienia z macicy | |
WO2009061569A1 (en) * | 2007-11-05 | 2009-05-14 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
US8299050B2 (en) * | 2008-01-29 | 2012-10-30 | Laboratoire Hra-Pharma | Method for treating uterine fibroids |
TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
EP2545922A1 (en) * | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
NZ702467A (en) | 2012-05-31 | 2016-07-29 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
ES2688821T3 (es) | 2012-11-02 | 2018-11-07 | Repros Therapeutics Inc. | Métodos y composiciones para tratar afecciones dependientes de la progesterona |
US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
JP6995757B2 (ja) | 2015-12-23 | 2022-01-17 | オリック ファーマシューティカルズ,インク. | グルココルチコイド受容体の阻害剤 |
PT3523315T (pt) | 2016-10-07 | 2021-04-29 | Oric Pharmaceuticals Inc | Inibidor de recetor de glucocorticoide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622943A (en) | 1992-05-06 | 1997-04-22 | The Medical College Of Hampton Roads | Minimizing progestin associated breakthrough bleeding |
WO1993021926A1 (en) * | 1992-05-06 | 1993-11-11 | Medical College Of Hampton Roads | Minimizing progestin associated breakthrough bleeding |
-
1995
- 1995-02-02 KR KR1019960705470A patent/KR100370908B1/ko not_active IP Right Cessation
- 1995-02-02 HU HU9602668A patent/HU226276B1/hu not_active IP Right Cessation
- 1995-02-02 CA CA002186953A patent/CA2186953C/en not_active Expired - Lifetime
- 1995-02-02 DK DK95919986T patent/DK0806952T3/da active
- 1995-02-02 PL PL95316533A patent/PL316533A1/xx unknown
- 1995-02-02 MX MX9603889A patent/MX9603889A/es not_active IP Right Cessation
- 1995-02-02 DE DE59510626T patent/DE59510626D1/de not_active Expired - Lifetime
- 1995-02-02 UA UA96104324A patent/UA37259C2/uk unknown
- 1995-02-02 AT AT95919986T patent/ATE235907T1/de active
- 1995-02-02 EP EP95919986A patent/EP0806952B1/de not_active Expired - Lifetime
- 1995-02-02 WO PCT/EP1995/000394 patent/WO1996023503A1/de active IP Right Grant
- 1995-02-02 AU AU25611/95A patent/AU714959B2/en not_active Ceased
- 1995-02-02 PT PT95919986T patent/PT806952E/pt unknown
- 1995-02-02 ES ES95919986T patent/ES2196063T3/es not_active Expired - Lifetime
- 1995-02-02 JP JP8523189A patent/JPH10512889A/ja not_active Withdrawn
- 1995-02-02 SK SK1219-96A patent/SK282570B6/sk unknown
-
1996
- 1996-08-01 FI FI963049A patent/FI117850B/fi not_active IP Right Cessation
- 1996-10-01 NZ NZ287024A patent/NZ287024A/en not_active IP Right Cessation
- 1996-10-01 NO NO964155A patent/NO964155D0/no not_active Application Discontinuation
-
2000
- 2000-07-12 US US09/615,060 patent/US6451780B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0806952B1 (de) | 2003-04-02 |
WO1996023503A1 (de) | 1996-08-08 |
NO964155L (no) | 1996-10-01 |
ATE235907T1 (de) | 2003-04-15 |
NZ287024A (en) | 2001-03-30 |
SK282570B6 (sk) | 2002-10-08 |
EP0806952A1 (de) | 1997-11-19 |
CA2186953A1 (en) | 1996-08-08 |
FI963049A (fi) | 1996-10-01 |
AU2561195A (en) | 1996-08-21 |
JPH10512889A (ja) | 1998-12-08 |
HUT75930A (en) | 1997-05-28 |
PL316533A1 (en) | 1997-01-20 |
US6451780B1 (en) | 2002-09-17 |
PT806952E (pt) | 2003-08-29 |
ES2196063T3 (es) | 2003-12-16 |
KR100370908B1 (ko) | 2003-04-10 |
HU226276B1 (en) | 2008-07-28 |
FI117850B (fi) | 2007-03-30 |
FI963049A0 (fi) | 1996-08-01 |
HU9602668D0 (en) | 1996-11-28 |
SK121996A3 (en) | 1997-05-07 |
NO964155D0 (no) | 1996-10-01 |
KR970704451A (ko) | 1997-09-06 |
DK0806952T3 (da) | 2003-06-16 |
UA37259C2 (uk) | 2001-05-15 |
CA2186953C (en) | 2009-11-10 |
AU714959B2 (en) | 2000-01-13 |
DE59510626D1 (de) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9603889A (es) | Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional. | |
SG72623A1 (en) | Menstrual shorts having improved fastening system | |
ZA894728B (en) | A new pharmaceutical formulation as well as a process for its preparation | |
CA2221753A1 (en) | Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast | |
NZ325060A (en) | Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone | |
ATE222494T1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
BG101427A (en) | Competitive progesterone antagonists for regulating female fertility as required | |
NO20005145D0 (no) | FremgangsmÕte for behandling av fertilitetsproblemer | |
WO2002056903A3 (en) | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators | |
NZ506622A (en) | 3',3'-N-bis-substituted macrolide LHRH antagonists | |
GR3025530T3 (en) | Antihypertensive benzopyran derivatives | |
EP0370300A3 (de) | Cyclopropyl-Substituierte Azolylmethylcarbinole, Verfarhren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
NZ504351A (en) | Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen | |
ES2148742T3 (es) | Dibenz(a,f)azulenos sustituidos y procedimientos de preparacion. | |
NZ330603A (en) | Hyaluronic acid derivatives used as cervical ripening agents | |
JPS6485990A (en) | Antihypertestoeronemia agent | |
JPS53117349A (en) | Interruption system | |
UA32373A (uk) | Спосіб реабілітації жінок, які перенесли атонічні маткові кровотечі з акушерською гістеректомією | |
GB2369574A (en) | Initiation of oestrus | |
ES1039452U (es) | Placa de osteotomia triple de cadera mejorada. | |
UA32122A (uk) | Спосіб профілактики розвитку еклампсій | |
ES2086413T3 (es) | Utilizacion de agentes antigestagenos para la preparacion de medicamentos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |